Clinical Trials Browser

Phase 2 × osimertinib × 30 days × Clear all

NCT03191149 2026-03-19

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06303167 2026-03-19

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Phase 2 Active not recruiting

19 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02971501 2026-03-17

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

7 enrolled 9 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06194448 2026-03-06

NEOLA

Phase 2 Active not recruiting

Lung Neoplasms

NCT05526755 2026-03-04

TARGET

Phase 2 Active not recruiting

Stage II-IIIB Non-small Cell Lung Carcinoma

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Phase 2 Active not recruiting

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT04606771 2026-02-27

CoC

Phase 2 Active not recruiting

30 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06741085 2026-02-18

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

Phase 2 Recruiting

Non Small Cell Lung Cancer Metastatic